Compare CURI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURI | CTMX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.8M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | CURI | CTMX |
|---|---|---|
| Price | $4.62 | $4.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $6.00 | ★ $6.50 |
| AVG Volume (30 Days) | 768.8K | ★ 2.0M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | $66,595,000.00 | ★ $113,631,000.00 |
| Revenue This Year | $42.19 | N/A |
| Revenue Next Year | $7.55 | N/A |
| P/E Ratio | ★ N/A | $17.32 |
| Revenue Growth | ★ 28.62 | N/A |
| 52 Week Low | $1.47 | $0.40 |
| 52 Week High | $7.15 | $4.62 |
| Indicator | CURI | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 57.36 |
| Support Level | $4.42 | $3.78 |
| Resistance Level | $5.00 | $4.20 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 34.48 | 73.88 |
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.